PTPRG — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7509205	1.00	14/20
SCHEMBL9232779	0.76	9/20
SCHEMBL4019876	0.67	9/20
SCHEMBL7823399	0.75	8/20
SCHEMBL1800354	0.50	8/20
SCHEMBL7830138	1.00	7/20
SCHEMBL4021401	0.69	7/20
SCHEMBL1308406	0.62	7/20
SCHEMBL4018614	0.48	7/20
SCHEMBL11817650	0.76	6/20
SCHEMBL6550957	0.67	6/20
SCHEMBL4015249	0.57	6/20
SCHEMBL11822185	0.53	6/20
SCHEMBL2772310	0.51	6/20
SCHEMBL1940433	0.43	6/20
SCHEMBL1941188	0.42	6/20
SCHEMBL11820877	0.69	5/20
SCHEMBL7825081	0.69	5/20
SCHEMBL11227010	0.61	5/20
SCHEMBL11565647	0.59	5/20

Clinical trials — most relevant to PTPRG by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy	PHASE4	COMPLETED
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia	PHASE3	RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer	PHASE2	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes	PHASE1	COMPLETED
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
The T1DWATCH Study: a Screening for Type 1 Diabetes Autoantibodies in Children for Early Detection and Intervention.	nan	NOT_YET_RECRUITING
CircularRNA-microRNA-mRNA Regulatory Axis in IVF	nan	NOT_YET_RECRUITING
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Ruxolitinib in Patients With Myelofibrosis	nan	UNKNOWN
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus?	nan	COMPLETED
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PTPRG binder may also engage these)

Protein	Name	Similarity
Q05909	—	1.000	Q05909 →
Q98936	—	1.000	Q98936 →
Q8BR86	—	0.978	Q8BR86 →
Q8IZU9	—	0.977	Q8IZU9 →
Q86TH1	—	0.975	Q86TH1 →
P57097	—	0.975	P57097 →
Q9R187	—	0.975	Q9R187 →
Q90Y90	—	0.974	Q90Y90 →
Q60805	—	0.973	Q60805 →
Q9WU72	—	0.973	Q9WU72 →
O94933	—	0.973	O94933 →
A6QLD2	—	0.973	A6QLD2 →
Q8JZL1	—	0.972	Q8JZL1 →
MERTK	Tyrosine-protein kinase Mer	0.972	landscape →
Q9UNE0	—	0.972	Q9UNE0 →
F3	Tissue factor	0.972	landscape →
Q7TSK7	—	0.972	Q7TSK7 →
Q9BXP8	—	0.971	Q9BXP8 →
Q8BLU0	—	0.971	Q8BLU0 →
Q9NZU1	—	0.971	Q9NZU1 →
O75129	—	0.971	O75129 →
P24055	—	0.971	P24055 →
Q58EG3	—	0.971	Q58EG3 →
O43155	—	0.971	O43155 →
Q8QHJ9	—	0.970	Q8QHJ9 →
Q3SXY7	—	0.970	Q3SXY7 →
Q6RKD8	—	0.970	Q6RKD8 →
Q6L8S8	—	0.970	Q6L8S8 →
Q8N8Z6	—	0.970	Q8N8Z6 →
Q9JJY4	—	0.970	Q9JJY4 →